Drug intelligence / Profile preview

AMT 2003

Development stage: Discontinued
Lead developer: Auron Healthcare
Modality: Small Molecules
Administration: Intramuscular

Overview

AMT 2003 (also known as Auron Misheil Therapy) is an investigational small molecule drug developed by Auron Healthcare for the treatment of advanced cancers, including colorectal cancer, liver cancer, cervical cancer, and other solid tumors. It was administered intramuscularly and classified as an antineoplastic agent with immunostimulant properties. The drug aimed to stimulate the immune system to target and fight cancer cells. Development reached up to phase 3 clinical trials in several indications but was ultimately discontinued without approval for any indication.

Other names: Auron Misheil Therapy

Beyond the preview

Go deeper on AMT 2003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMT 2003.

Explore the full profile